Varenicline for Smoking
Trial Summary
What is the purpose of this trial?
In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that the investigators offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.
Research Team
Jessica Megan Cook, PhD
Principal Investigator
William S. Middleton Memorial Veterans Hospital, Madison, WI
Neal M Doran, PhD
Principal Investigator
VA San Diego Healthcare System, San Diego, CA
Eligibility Criteria
This trial is for veterans with a smoking addiction who aren't ready to quit yet. It's designed to help increase their chances of making quit attempts and achieving long-term abstinence from smoking.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Motivation-Phase Treatment
Participants receive either varenicline or NRT mini-lozenges for 12 weeks, along with 5 phone counseling sessions focused on smoking reduction
Follow-up
Participants are monitored for smoking abstinence and quit attempts at 6 and 12 months post-study entry
Treatment Details
Interventions
- Varenicline
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor